TABLE 4.
Effect of drugs on the APD of cardiomyocytes incubated with 3 μM ATO.
| Drugs | Subject | Working channel | Control APD90 (ms) | ATO APD90 (ms) | Drug + ATO APD90 (ms) | r |
|---|---|---|---|---|---|---|
| 1 μM fexofenadine (Yan et al., 2017) | HEK293 | I Kr | N/A | N/A | N/A | N/A |
| NRVMs | N/A | 171.25 ± 10.58 | 396.43 ± 25.33 | 233.30 ± 18.75 | 72.44% | |
| hiPS-CMs | N/A | 706.98 ± 23.71 | 1164.71 ± 40.25 | 942.86 ± 103.11 | 48.47% | |
| 25 nM nisoldipine (Ficker et al., 2004) | Guinea pig VMs | I CaL | 495 ± 40 | 880 ± 61 | 686 ± 36 | 50.39% |
| 10 μM resveratrol | hiPS-CMs (Yan et al., 2017) | I CaL | 706.98 ± 23.71 | 1164.71 ± 40.25 | 942.86 ± 103.11 | 48.47% |
| Guinea pig VMs (Zhao et al., 2014) | I Kr | 429.1 ± 26.5 | 948.3 ± 63.7 | 522.6 ± 26.3 | 81.99% | |
| 10 μM resveratrol simulation | ENDO | I CaL & I Kr | 306 | 391 | 357 | 40.00% |
| MCELL | I CaL & I Kr | 410 | 602 | 511 | 47.40% | |
| EPI | I CaL & I Kr | 307 | 394 | 360 | 39.08% |